A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Investigate the Efficacy Safety and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Dravet Syndrome

Brief description of study

The purpose of this study is to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children (2-17) and adults (18-65) with Dravet Syndrome (DS).

The study consists of the following periods for all participants: Screening (approximately 5 weeks), Titration (3 weeks or Days 1 to 21), and Maintenance (12 weeks or Days 22 to 105).

Clinical Study Identifier: s25-00003

ClinicalTrials.gov Identifier: NCT06660394

Principal Investigator: Dana Price.

Other Investigators: Angela M. Curcio, Daniel Friedman, Erin K Conway, Christopher Elder, Benjamin N. Blond, Claude Steriade, Andrew Charles Christiana, Sarah Levy.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies